Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001697862-25-000028
Filing Date
2025-05-08
Accepted
2025-05-08 06:39:56
Documents
19
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 6-K a01coverpageforsecfilingq1.htm 6-K 19231
2 EX-99.1 a02earningspressreleaseq1.htm EX-99.1 100616
3 EX-99.2 argxq1earningscall.htm EX-99.2 16732
4 argenx_logoxrgb.jpg GRAPHIC 112817
5 argxq1earningscall001.jpg GRAPHIC 102862
6 argxq1earningscall002.jpg GRAPHIC 251733
7 argxq1earningscall003.jpg GRAPHIC 90593
8 argxq1earningscall004.jpg GRAPHIC 75984
9 argxq1earningscall005.jpg GRAPHIC 114779
10 argxq1earningscall006.jpg GRAPHIC 107227
11 argxq1earningscall007.jpg GRAPHIC 94318
12 argxq1earningscall008.jpg GRAPHIC 127728
13 argxq1earningscall009.jpg GRAPHIC 131440
14 argxq1earningscall010.jpg GRAPHIC 92134
15 argxq1earningscall011.jpg GRAPHIC 121712
16 argxq1earningscall012.jpg GRAPHIC 148663
17 argxq1earningscall013.jpg GRAPHIC 97292
18 argxq1earningscall014.jpg GRAPHIC 80369
19 argxq1earningscall015.jpg GRAPHIC 114581
  Complete submission text file 0001697862-25-000028.txt   2695293
Mailing Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052
Business Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052 32 (9) 310 34 00
ARGENX SE (Filer) CIK: 0001697862 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38097 | Film No.: 25923717
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)